Who Will Solve The Shortage Problem? Hospital Non-Profit Is Latest Idea
Non-profit probably won’t ever be significant threat to industry – but frustration with chronic shortages could prompt policy changes that are.
You may also be interested in...
To encourage drug compounding pharmacies to register as 503B drug outsourcing facilities, FDA plans to propose assigning these pharmacies a lower risk category, thus subjecting them to less stringent GMP controls if they make limited volumes of drugs as part of a “2018 Compounding Policy Priorities Plan” announced by FDA Commissioner Scott Gottlieb.
Targeted Importation: A Drug Pricing Mechanism For 'Predatory Actors' And An A-Pauling HHS Confirmation Dilemma
For those old drug re-pricing situations that reach headline and/or US congressional visibility, a tweak to the importation debate might offer a response.
Changing the Subject (Part 2): Turning Turing Around By Offering A “National Center Of Pharmaceutical Supply”
Rather than try to “win” the drug pricing debate, the biopharma sector may be better served by coming up with new ideas to change the subject. We outlined our case for taking this approach – and the model for ideas that serve that goal – here. Now we offer the first proposal: a national center for off-patent pharmaceutical production.